NasdaqGS - Nasdaq Real Time Price USD

Amylyx Pharmaceuticals, Inc. (AMLX)

4.5600
-0.0200
(-0.44%)
As of 1:44:08 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
87,371
87,371
380,786
22,230
0
Cost of Revenue
124,633
124,633
25,441
2,993
0
Gross Profit
-37,262
-37,262
355,345
19,237
0
Operating Expense
254,618
254,618
316,543
220,578
82,688
Operating Income
-291,880
-291,880
38,802
-201,341
-82,688
Net Non Operating Interest Income Expense
13,809
13,809
16,155
4,291
36
Other Income Expense
-24,065
-24,065
-660
-551
-5,279
Pretax Income
-302,136
-302,136
54,297
-197,601
-87,931
Tax Provision
-393
-393
5,026
774
0
Net Income Common Stockholders
-301,743
-301,743
49,271
-198,375
-87,931
Diluted NI Available to Com Stockholders
-301,743
-301,743
49,271
-198,375
-87,931
Basic EPS
-4.43
--
0.73
-3.39
-1.59
Diluted EPS
-4.43
--
0.70
-3.39
-1.59
Basic Average Shares
68,142.1580
--
67,234.4650
58,495.5870
55,216.0130
Diluted Average Shares
68,142.1580
--
69,991.3400
58,495.5870
55,216.0130
Total Operating Income as Reported
-314,731
-314,731
38,802
-201,341
-82,688
Total Expenses
379,251
379,251
341,984
223,571
82,688
Net Income from Continuing & Discontinued Operation
-301,743
-301,743
49,271
-198,375
-87,931
Normalized Income
-278,921.7232
-278,921.7232
49,271
-198,375
-87,931
Interest Income
13,809
13,809
16,155
4,291
36
Interest Expense
--
--
--
--
0
Net Interest Income
13,809
13,809
16,155
4,291
36
EBIT
-291,880
-291,880
38,802
-201,341
-82,688
EBITDA
-290,976
-290,976
39,890
-200,854
-82,636
Reconciled Cost of Revenue
124,633
124,633
25,441
2,993
0
Reconciled Depreciation
904
904
1,088
487
52
Net Income from Continuing Operation Net Minority Interest
-301,743
-301,743
49,271
-198,375
-87,931
Total Unusual Items Excluding Goodwill
-22,851
-22,851
0
--
--
Total Unusual Items
-22,851
-22,851
0
--
--
Normalized EBITDA
-268,125
-268,125
39,890
-200,854
-82,636
Tax Rate for Calcs
0
0
0.0001
0.0002
0
Tax Effect of Unusual Items
-29.7232
-29.7232
0
0
0
12/31/2021 - 1/7/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VTYX Ventyx Biosciences, Inc.
1.3150
+12.39%
 
COGT Cogent Biosciences, Inc.
4.9350
-0.90%
 
TRVI Trevi Therapeutics, Inc.
6.63
+0.45%
 
SLDB Solid Biosciences Inc.
2.8500
+2.89%
 
MTSR Metsera, Inc.
23.25
-6.10%
 
TSHA Taysha Gene Therapies, Inc.
2.1350
+1.67%
 
SLNO Soleno Therapeutics, Inc.
77.45
+1.56%
 
ACAD ACADIA Pharmaceuticals Inc.
17.39
+2.72%
 
QURE uniQure N.V.
12.71
+3.76%
 
CCCC C4 Therapeutics, Inc.
1.4900
-3.25%